| __timestamp | Amicus Therapeutics, Inc. | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 84580000 |
| Thursday, January 1, 2015 | 76943000 | 86943000 |
| Friday, January 1, 2016 | 104793000 | 84493000 |
| Sunday, January 1, 2017 | 149310000 | 64988000 |
| Monday, January 1, 2018 | 270902000 | 74951000 |
| Tuesday, January 1, 2019 | 286378000 | 62331000 |
| Wednesday, January 1, 2020 | 308443000 | 28607000 |
| Friday, January 1, 2021 | 272049000 | 32228000 |
| Saturday, January 1, 2022 | 276677000 | 46600000 |
| Sunday, January 1, 2023 | 152381000 | 54886000 |
Unlocking the unknown
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amicus Therapeutics, Inc. and Dynavax Technologies Corporation have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Amicus Therapeutics increased its R&D budget by over 220%, peaking in 2020 with a 547% rise from its 2014 spending. This surge underscores Amicus's aggressive pursuit of new therapies. In contrast, Dynavax Technologies saw a 35% decrease in R&D spending over the same period, reflecting a more conservative approach.
The data reveals a pivotal shift in 2018 when Amicus's R&D expenses surpassed Dynavax's by nearly 260%. This trend continued, highlighting Amicus's strategic focus on expanding its research capabilities. As the biotech landscape evolves, these spending patterns offer insights into each company's future trajectory.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and Amicus Therapeutics, Inc.
Comparing Innovation Spending: Novo Nordisk A/S and Dynavax Technologies Corporation
Analyzing R&D Budgets: Novartis AG vs Dynavax Technologies Corporation
Analyzing R&D Budgets: Zoetis Inc. vs Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Amicus Therapeutics, Inc.
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Perrigo Company plc vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Galapagos NV